NCT04674189View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

2,357

Participants

Timeline

Start Date

December 23, 2020

Primary Completion Date

June 8, 2022

Study Completion Date

June 8, 2022

Conditions
CoronavirusCovid19SARS-CoV-2Severe Acute Respiratory Syndrome
Interventions
BIOLOGICAL

CVnCoV Vaccine

Intramuscular injection

DRUG

Placebo

Intramuscular injection

Trial Locations (1)

55131

Universitätsmedizin der Johannes-Gutenberg-Universität Mainz Langenbeckstr. 1, Mainz

Sponsors

Lead Sponsor

CureVac
All Listed Sponsors
collaborator

German Federal Ministry of Education and Research

OTHER_GOV

lead

CureVac

INDUSTRY

NCT04674189 - A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 | Biotech Hunter | Biotech Hunter